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oxygen to patients suffering from neurological
impairment. In 1963, physicians at the Hospital for Sick
Children in Toronto, ventilating infants with a Bird
Mark VIII machine, achieved their first survivor
without air leak or cerebral abnormalities (1). Soon
thereafter, low levels of positive end-airway pressure
(PEEP) were used to overcome the gradual decline in
functional residual capacity (FRC) and minimize
atelectasis. PEEP effectively stents open the lung to
prevent collapse at the end expiratory point. Similarly,
INTRODUCTION
Prior to the mid 1960s, mechanical ventilators were
designed to provide alveolar ventilation and additional
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ABSTRACT:  The improvement in survival in premature infants associated with the evolution of
mechanical ventilation has been accompanied by an increase in ventilator induced lung injury. High
frequency ventilation has been shown to reduce the incidence of ventilator induced lung injury and
hence chronic lung disease in the very low birth weight infant. The evolution in understanding how to
best use high frequency ventilation in this population has prompted us to ask whether similar strategies
to optimize lung volumes on conventional mechanical ventilation can minimize chronic lung disease in
the neonate. We retrospectively reviewed the medical charts of 51 extremely low birth weight infants
born in Kingston, Ontario in two epochs, 1990 to 1991 and 1999 to 2000, for ventilatory strategy and
outcome. From our review, it is clear that surfactant therapy rapidly changes lung mechanics by
improving pulmonary compliance and that lung damage may result if there are not changes in the
ventilatory management to reflect the altered compliance. Early ventilation strategies during the
apparently stable "honeymoon period" in a patient with respiratory distress syndrome (RDS) has
significant implications on long term morbidity. In the era prior to the use of surfactant, 30% of infants
died and 40% developed chronic lung disease (CLD). Immediately following the use of surfactant ,
mortality was reduced to 18%, however, the incidence of CLD increased to 78%. In the most recent era,
following 10 years of experience with surfactant and mechanical ventilation, morbidity was 17% and
CLD 21%.  This study demonstrates that a particularly crucial time is in the immediate period
following surfactant administration. The use of lower peak inspiratory pressure (PIP) and mean airway
pressure (MAP) over the first 24 hours and an increase in the use of synchronous intermittent
mandatory ventilation (SIMV) was associated with an improved outcome. The challenge remaining is
to determine how to best utilize a conventional mode of ventilation to best optimize lung volume and
protect the immature lung.96 Ventilatory Management Vol. 9 No. 2
continuous positive airway pressure (CPAP) during
mechanical ventilation stents open the lung throughout
the entire respiratory cycle, preventing collapse and
permitting lower pressures to be used for movement of
gas. CPAP and PEEP became mainstays of mechanical
ventilation during acute lung injury. In the early 1970s,
intermittent mandatory ventilation (IMV) that delivered
a certain volume at specific time intervals interspersed
with the patient's respiratory efforts was the common
method of neonatal ventilatory support.  
Positive pressure ventilation (PPV) utilizes
supraphysiologic pressues to induce the flow of gas into
the lung. While PPV reduced mortality, an increase in
morbidity was seen amongst survivors, in part related to
ventilator management of the high pressures. In 1974,
Webb and Tierney demonstrated that PPV could induce
lung injury manifested by edema hemorrhage and
hyaline membrane formation (2). Asynchrony between
the ventilator delivered volume and spontaneous
breathing is common during conventional intermittent
mandatory ventilation and may result in irregular
systemic and cerebral flow patterns, suboptimal gas
exchange, barotraumas, airleak syndrome, pulmonary
hemorrhage, intraventricular hemorrhage,
periventricular leukomalacia, and chronic lung disease
(1,3). These complications may be avoided by sedatives
or muscle relaxants to minimize the infant's
spontaneous breathing.  Alternatively the ventilator rate
and inspiratory time may be manipulated to be
synchronous with spontaneous breaths. A third
approach is patient-triggered ventilation in which the
breath delivered by the ventilator is triggered by the
early spontaneous breathing effort. There are two types
of patient-triggered ventilation: assist control, where
every spontaneous breath triggers a ventilator breath
and synchronized intermittent mandatory ventilation
(SIMV), where the ventilator is only triggered on
selected spontaneous breaths (3).  Infant ventilators may
use one of several methods to detect spontaneous
breathing. These include abdominal movement,
thoracic impedance through electrocardiogram leads,
and sensors of airway pressure or flow (4). Recent
advances in neonatal conventional mechanical
ventilation (CMV) include increased sensitivity and
hence improved patient-ventilator synchrony, pressure
limited machines, graphics, calculations of gas leak,
tidal volume (Vt), minute ventilation, and flow volume
loops. Additionally, impact of new methods of neonatal
ventilatory management including pressure support,
volume guarantee, and non-invasive ventilation such as
the use of continuous positive airway pressure (CPAP)
are continually being studied (5-7).
The most important advancement in neonatal care
was the utilization of surfactant. Surfactant proteins
were isolated and characterized in the 1970s and 1980s
and the genes responsible for these proteins were cloned
and sequenced (8). The clinical benefit from surfactant
comes from its ability to lower alveolar surface tension
and therefore increase compliance, increase stability
and maintain small airway patency. 
"PROTECTIVE LUNG STRATEGY" - HIGH
FREQUENCY OSCILLATORY VENTILATION
VERSUS CONVENTIONAL VENTILATION
High frequency oscillatory ventilation (HFOV) is a
ventilatory strategy using low tidal volumes with low
phasic pressure changes and supraphysiologic
ventilatory frequencies.  While the initial major HFOV
study provided disappointing results, this has been
attributed to some misunderstandings of how HFOV
should be used (9). The Provo Multicenter Early High-
Frequency Oscillatory Ventilation Trial concluded that
when used early with a lung recruitment strategy,
HFOV after surfactant replacement resulted in clinical
outcomes consistent with a reduction in both acute and
chronic lung injury (10). Reimensberger et al (11).
managed 32 very low birth weight (VLBW) infants
with first intention HFOV and compared this group to
39 historical controls managed with CMV and found
that early use of HFOV with lung volume optimization
significantly shortened the duration of respiratory
support and improved pulmonary outcome. In a more
recent study, Courtney et al. demonstrated a small but
significant benefit of HFOV versus SIMV in terms of
the pulmonary outcome of VLBW infants (12). In this
study, HFOV did not result in an increase in the
occurrence of other complications of premature birth.
It is apparent from the early use of HFOV that the
outcome is dependant on the strategy applied and the
individual disease process. If the lung is expanded and
cyclical collapse is prevented, underlying disease
process(es) may recover, limiting further inflammatory
response (and hence chronic lung disease (CLD)) and
potentially support endogenous surfactant production.
Ventilator induced lung injury (VILI) and hence CLD
may be reduced by using HFOV with a lung recruitment
approach. The question then becomes: can similar
results be achieved by using CMV with an "open lung"
in VLBW neonates? Similarly, adult studies involving
patients with acute respiratory distress syndrome and in
intensive care demonstrated that protective strategies
with an open lung approach (PEEP above the lower
inflection point on the static pressure-volume curve,
low tidal volume, permissive hypercapnia) in
comparison to CMV resulted in improved survival,
higher rate of weaning from mechanical ventilation and
a lower rate of ventilator induced lung injury (13-15).
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demonstrate that CMV with sufficient level of PEEP
and small driving pressure amplitudes is as effective as
HFOV in maintaining optimal gas exchange, improving
lung mechanics, and preserving exogenous surfactant.
Thome demonstrated that HFOV versus CMV with high
RR and low peak inspiratory pressures resulted in no
difference in lung injury (17). Other ventilatory factors
thought to play a role in outcome are the peak
inspiratory pressure (PIP) and the mean airway pressure
(MAP). HFOV uses lower PIP and MAP than does
CMV and recent trends have been towards lowering
pressures in CMV in an effort to minimize lung trauma.
PURPOSE
There is currently minimal published Canadian data
examining the ventilation experience in extremely low
birth weight infants. The purpose of this study is to
examine how CMV ventilation strategy has changed
over time in a Canadian tertiary level neonatology unit
and to determine how these changes have affected
patient outcome.  
METHODS
Study design
This study was conducted as a retrospective chart
review of two epochs, 1990-1991 and 1999-2000. The
use of surfactant in neonates with respiratory distress
syndrome (RDS) was begun in Kingston, Ontario in
July 1990. The eligible infants from these two epochs
were assigned to one of three groups: Group 1 -
Immediately pre introduction of surfactant - 1990;
Group 2 - Immediately post introduction of surfactant -
1990-1991; Group 3 - Ten years post introduction of
surfactant - 1999-2000. The two different time periods
were chosen in order to examine how ventilator
strategies on CMV have changed 1) following the
introduction of surfactant, and 2) with time. The
examination of data from both the pre and post
surfactant era as well as a comparison to more recent
techniques contributes to the novelty of the data
presented.
Patient inclusion criteria
Eligible patients: all live-born, mechanically
ventilated neonates weighing less than 1000 grams who
were admitted to the neonatal intensive care unit in
Kingston, Ontario during the two epochs .  
Data collection
For all eligible infants, the ventilator settings were
recorded for the first 72 hours of life. The median value
of the ventilator settings was calculated over the first
three 24 hour periods of life and the ranges and standard
deviations were recorded. Outcomes of interest were:
1) Ventilator settings during hours 0 - 72 of life 
2) Incidence of bronchopulmonary dysplasia (BPD)
as defined by use of supplemental oxygen at 36/40
weeks corrected gestational age
3) Total duration of O2 dependence
4) Total duration of mechanical ventilation
5) Incidence of severe intraventricular hemorrhage
(i.e. grade III/IV)
6) NICU mortality. 
STATISTICAL ANALYSIS
An unpaired t-test was used for parametric data.
Categorical data were analysed by means of a Fisher's
exact test or Chi2 analysis as appropriate. For all
testing, a p value of < 0.05 was accepted as significant.  
Comparisons were made between: 
1) Group 1 and Group 2  
2) Group 2 and Group 3  
RESULTS
There were 51 eligible neonates, all of whom were
included in the study.  All 51 of neonates were intubated
and ventilated. One child from group 2 was transferred
from Kingston and was considered lost to follow up. 
Group 1 (n = 10; 4 male (m) and 6 female (f)) 
Group 2 (n = 11; 6 m and 5 f)  
Group 3 (n = 30; 11 m and 19 f)  
There was no statistical difference between Groups 1
and 2 or Groups 2 and 3 with the exception of surfactant
use, which was by design (Tables 1 and 2).  
The neonates in Group 2 received an average of 1.5
doses of surfactant compared to the neonates in Group
3 receiving surfactant who received an average of 1.9
doses.  
Table 1. Comparison Between Groups 1 and 2
Group 1 (n=10)      Group 2 (n=11)    P Value
Mean BW (g) 798 (480-950)        823 (660-980)          NS
Mean GA (wks) 26.4 (23-29)           26.7  (24-30)           NS
Male 4 6 NS
Female    6 5 NS
Surfactant 0 11 P<0.0001
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Table 2. Comparison Between Groups 2 and 3
Group 2 (n=11)      Group 3 (n=30)    P Value
Mean BW (g) 823 (660-980) 778 (519-979)     NS
Mean GA (wks) 26.7 (24-30) 26 (24-32) NS
Male 6 11    NS
Female    5 19 NS
Mech. Ventilated 11 30        NS
Surfactant 11 24 NS
Pre Natal Steroids 8 13 NS
Respiratory morbidity
In Group 1, all infants were ventilated on an
intermittent mandatory mode (IMV). In this epoch,
IMV was available on both the Bear Cub and Sechrist
ventilators.  Median duration of mechanical ventilation
was 21 days (1-109) with a standard deviation of 35.6
days. In Group 2, all infants were ventilated on IMV.
Median duration of mechanical ventilation was 28 days
(2-75) with a standard deviation of 20.7 days.  
In Group 3, 9 infants were ventilated solely on IMV,
10 infants were ventilated solely by synchronized IMV
mode (Babylog), and 11 were ventilated on a
combination of IMV and/or SIMV and/or assist control
(AC). The median duration of mechanical ventilation in
this group was 30.0 days (1-73) with a standard
deviation of 19.9 days. Table 3 records the ventilator
parameters used in the three groups. Of note, there was
not a significant difference in PIP and MAP between
groups 1 and 2 in the first 24 hour period whereas there
was a significant difference in these variables between
groups 2 and 3 over the first 24 hours. There were
ventilator settings recorded in Group 3 that were not
noted in the earlier time periods. These include
inspiratory time (IT) and inspiratory to expiratory ratio
(I:E). The inspiratory times for the first, second, and
third 24 hours periods were 0.47 (0.40-0.53), 0.47
(0.42-0.55), and 0.48 (0.42-0.55) respectively. The I:E
for the first, second, and third 24 hour periods were3.5
(1.9-10.4), 4.7 (1.6-10.7), and 3.5 (1.2-10.7)
respectively. Tables 4 and 5 compare duration of
ventilation and oxygen dependence between the three
study groups.  
Morbidity and mortality
In the pre-surfactant era Group 1, 30.0% (3 of 10)
Table 3. Ventilator Parameters in Groups 1, 2, and 3
Group number 0-24 Hours 24-48 Hours  48-72 Hours  
PIP 1 25.5 (18-35) 26.8 (18-43) 30.0 (20-43)
2 23 (18-30) 20 (14-23) 20 (18-25)*
3 18 (13.5-24)# 16 (12-22) 16 (12-23)#
MAP 1 10.5 (5.5-12.5) 12 (7.5-17) 12 (9-16)
2 9 (7-21) 7 (6-10)* 6.5 (6-10)*
3 7.6 (4-10.5)# 6.8 (3-11) 7.2 (3-12)
RR 1 55 (15-95) 67.5 (30-130) 72.5 (36-120)
2 35 (20-60) 22 (10-60) 35 (10-45)
3 27.5 (15-40)# 22.5 (10-45) 30 (10-60)
PEEP 1 5 (4-5) 5 (4-6) 4.5 (4-6)
2 5 (4-6)* 5 (4-6)* 5 (4-5)*
3 5 (4-5) 5 (4-7) 5 (3-6)
CO2 1 44.5 (25-56) 49 (33-58.5) 45 (34-62)
2 37 (26-69) 38 (30-50)* 39 (30-48)
3 37.1 (29.7-45.9) 43.1 (32.2-73.3) 38.8 (32.0-63.6)
* significant difference between groups 1 & 2  
# significant difference between groups 2 & 3
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Figure 1: Outcomes in Groups 1, 2, and 399 McGill Journal of Medicine 2006
infants did not survive to discharge. The mean age at
death in these infants was 10 (1-18) days. The cause of
death was respiratory failure in all three cases. In Group
2 (ie since the introduction of surfactant use) 18.1% (2
of 11) of infants did not survive to discharge. The mean
age at death in this group was 4.5 (2-7) days. Causes of
death were respiratory failure and pulmonary
hypoplasia. In Group 3, 16.7% (5 of 30) of infants
expired. The mean age at death in this group was 23.3
(2-64) days. Causes of death included periventricular
leukomalacia, intraventricular hemorrhage, necrotizing
enterocolitis, candida sepsis, gram negative sepsis, and
respiratory failure. Figure 1 illustrates the comparisons
of these outcomes amongst the three study groups.
Table 4. Duration of Oxygen Dependence and Ventilation (Groups 1
and 2)
Group 1   Group 2       P Value
Median O2 Dep (d) 45  (1-148) 58  (2-145)          0.8
Median O2 Dep (CGA)  34  (23-47)   36  (26-65)          0.3
Median Duration of Mech Vent (d)
21  (1-109) 28    (2-75)         0.7
Table 5. Duration of Oxygen Dependence and Ventilation (Groups 2
and 3)
Group 2        Group 3         P Value
Median O2 Dep (d) 58  (2-145) 34.5 (1-73)        0.04
Median O2 Dep (CGA)  36  (26-65) 32 (26-41) 0.07
Median Duration of Mech Vent (d)
28    (2-75) 30 (1-73) 0.7
DISCUSSION
While the introduction of surfactant has significantly
reduced the mortality from respiratory distress
syndrome, chronic lung disease remains a significant
problem in the extremely low birth weight infant
(20.7% in 1999). By comparing extremely low birth
weight infants who received surfactant (Group 2) versus
those who did not (Group 1), it is possible to determine
the effect of surfactant in decreasing the morbidity and
mortality from respiratory distress syndrome. The
observation between the two groups of patients born
since the routine use of surfactant, i.e. one early in the
surfactant era (Group 2) and a second cohort born ten
years later (Group 3) were made in order to determine
how changes in ventilatory management may affect
neonatal outcome. It is clear that surfactant therapy
rapidly changes lung mechanics by improving
pulmonary compliance. However, it is evident that
surfactant therapy alone does not decrease the incidence
of chronic lung disease (40.0% incidence in Group 1 vs
77.8% incidence in Group 2). In group 1, higher PIP and
MAP was required in order to overcome the very low
compliance of the surfactant deficient lung. It is likely
that the high pressures used contributed significantly to
the incidence of chronic lung disease in this group. In
group 2, the PIP and MAP were not significantly lower
in the first 24 hours. While mortality was significantly
lower, the incidence of CLD is substantially higher in
the infants immediately following the introduction of
surfactant (Group 2), when compared to Group 1.
Although surfactant therapy improved lung compliance,
in the absence of a significant decrease in pressures in
the first 24 hours, damage to the lung occurred. This
illustrates how even brief periods of a mechanical
ventilatory strategy on CMV may cause lung injury and
affect outcome in the presence of changing pulmonary
compliance. In comparison to Group 2, the infants in
Group 3 had a significantly lower mortality rate and
incidence of CLD. This likely reflects the impact of a
change in ventilator management given that there were
no other significant baseline differences between these
two groups. Evolution in ventilation strategies included
an increase in the use of SIMV, lower PIP, and lower
MAP. It is of significance that the PIP and MAP were
statistically lower over the first twenty-four hour time
period in Group 3. The lower PIP and MAP in Group 3,
combined with advances in pressure/volume limitation,
has the effect of limiting barotraumas and hence
reducing the incidence of CLD. The duration of O2
dependence is also significantly lower in Group 3. This
may reflect improvements in strategies to optimize lung
recruitment. The fluid management regime and the
incidence of patent ductus arteriosis were not reviewed
during this study and should be included in future
studies.
Following the results of this study, our question
remains: how can CMV and surfactant therapy continue
to be optimized? Certainly, all clinicians are aware that
of the need to limit volutrauma. Proven strategies
include minimizing the MAP, limiting the transalveolar
pressure, using small amplitudes (Vt 4-6 ml/kg) and the
use of high frequency oscillatory ventilation. However,
are there other strategies that we can utilize during
CMV that can further optimize patient outcome? Recent
animal and human studies show that CMV may perhaps
be just as effective as HFOV when an appropriate
"protective lung strategy" is used (17,18,19). Froese et
al. showed that early lung volume optimization
preserves surfactant life span by both decreasing the
rate of inactivation and allowing for endogenous
production (20). From these data, it seems that a "lung100 Ventilatory Management Vol. 9 No. 2
protective strategy" with early volume optimization and
surfactant therapy is an effective approach. Possible
strategies include using a high respiratory rate and
hence inducing an auto PEEP, determining and
implementing the optimal PEEP, early permissive
hypercapnea, and using shorter, more physiological
inspiratory times. Recent advances in ventilator
technology such as pressure support, volume guarantee,
volume support, and proportional assist modes are
designed to limit lung injury in the VLBW neonatal
population. A further approach may be to avoid
mechanical ventilation altogether and use NCPAP as is
suggested by the Scandinavian studies (7,21).
CONCLUSION
From these data we can conclude that while
surfactant therapy has proven benefits in improving
pulmonary mechanics, and hence the survival of
neonates, equally important is the ventilation strategy
used on the premature lung with changing compliance.
From this study, it appears that surfactant therapy
actually increased the risk of CLD in 1990-1991. Early
ventilation strategies during the apparently stable
"honeymoon period" in a patient with RDS has
significant implications on long term morbidity. As
demonstrated by this study, a particular crucial time is
in the immediate period following surfactant
administration. The learning curve experienced by
clinicians in the years following the widespread use of
exogenous surfactant has demonstrated a change
towards acting on clinically apparent changes in the
neonate, rather than a dependence on blood gas
measurements and chest radiograph findings.  This has
been aided by more recent advances in ventilator
technology (tidal volume and minute ventilation
measurements) and non-invasive monitoring
(transcutaneous CO2 measurements). The difficulty, as
demonstrated by the "open-lung" studies by NIH, etc. in
patients with ARDS, is to conduct randomized
controlled trials comparing strategies in CMV in the
neonate, in light of our evolving experience on how best
to use a conventional ventilator (13,15). The goal now
is to overcome these challenges and to continue to learn
how best to utilize a "conventional" mode of ventilation
to optimize lung volume and protect the immature lung.  
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